Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 26Leukemia, Myeloid, Acute 24Recurrence 12Sarcoma 7Lymphoma, Large B-Cell, Diffuse 6Neoplasm Metastasis 5Neurofibrosarcoma 4Neoplasms, Plasma Cell 4Lymphoma 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Thymoma 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Melanoma 2Lymphoma, Mantle-Cell 2Liposarcoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Leukemia 2Congenital Abnormalities 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Wilms Tumor 1

Interventions

Everolimus 7Nivolumab 6Cisplatin 6Temozolomide 5Bevacizumab 5lutetium Lu 177 dotatate 4Fluorouracil 4Carboplatin 4pembrolizumab 3avelumab 3atezolizumab 3Irinotecan 3Ipilimumab 3Etoposide 3Capecitabine 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2Immunoglobulin G 2IFL protocol 2Fluorodeoxyglucose F18 2Drug Therapy 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Neuroendocrine × selinexor × Clear all
NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Gabrail Cancer Center Research

Phase 2 Completed
14 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡